Ausgabe 4/2023
Inhalt (18 Artikel)
- editorial
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
Gabriel Rinnerthaler
- short review
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
Patrick Reimann, Thomas Winder
- Open Access
- short review
ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma
Angela Djanani
- Open Access
- short review
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma
Aysegül Ilhan-Mutlu, Ewald Wöll
- case report
Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
Sophie Roider-Schur, Sybille Machat, Leopold Öhler
- comment
Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
Isabel Heidegger, Andreas Pircher
- Open Access
- short review
Focal therapy in intermediate- and high-risk prostate cancer
Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat
- Open Access
- short review
Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment
Sazan Rasul, Stephan Korn
- Open Access
- short review
Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors
Petar Popov
- Open Access
- short review
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Ronald Heregger, Richard Greil
- short review
Management of malignant hypercalcemia in cancer patients—a short review
Clemens Petrasch, Petra Marics, Thomas Spanberger
- original report
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
Manal Atef, Layla M. Saleh, Noha Eisa, Sameh Shamaa
